

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 January 2023 (19.01.2023)



(10) International Publication Number
WO 2023/285987 A1

(51) International Patent Classification:

C12N 15/86 (2006.01) A61K 38/51 (2006.01)
C12N 15/87 (2006.01) C12N 15/63 (2006.01)

(21) International Application Number:

PCT/IB2022/056458

(22) International Filing Date:

13 July 2022 (13.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/221,883 14 July 2021 (14.07.2021) US

(71) Applicant: **MEIRAGTX UK II LIMITED** [GB/GB]; 92
Britannia Walk, London Aberdeenshire N1 7NQ (GB).

(72) Inventor: **GEORGIADIS, Anastasios**; c/o MEIRAGTX
UK II LIMITED, 92 Britannia Walk, London Aberdeenshire N1 7NQ (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: RETGC GENE THERAPY




Fig. 1

(57) Abstract: Provided herein are expression constructs, viral genomes, and vectors for the expression of retinal membrane guanylyl cyclase 1 (RetGC1), as well as pharmaceutical compositions comprising the vectors disclosed herein. Also provided are methods of using the expression constructs and vectors disclosed herein, including methods of treating a retinal disease in a subject in need thereof, wherein the retinal disease is associated with one or more mutations in the GUCY2D gene, the method comprising administering to the subject a vector disclosed herein.

[Continued on next page]

WO 2023/285987 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*